Journal of Neuroimmunology · 2015 · 22 citations · 24 references
Life SciencesImmunologyPharmacologyCellular ImmunologyImmunopharmacologyInflammationCytokine BiologyImmune Gene RegulationImmune SignalingMultiple SclerosisMultiple Sclerosis PharmacotherapyNeuroinflammationMultiple Sclerosis ImmunopathogenesisMultiple Sclerosis ImmunopathologyMultiple Sclerosis TherapyNeuroinflammation In Multiple SclerosisPharmaceutical Equivalence AssessmentPharmacogenomics Of ImmunomodulatorsTherapeutic Equivalence EvaluationTherapeutic Equivalence Ratings
Glatiramer acetate (Copaxone®; GA) is a non-biological complex drug for multiple sclerosis. GA modulated thousands of genes in genome-wide expression studies conducted in THP-1 cells and mouse splenocytes. Comparing GA with differently-manufactured glatiramoid Polimunol (Synthon) in mice yielded hundreds of differentially expressed probesets, including biologically-relevant genes (e.g. Il18, adj p<9e-6) and pathways. In human monocytes, 700+ probesets differed between Polimunol and GA, enriching for 130+ pathways including response to lipopolysaccharide (adj. p<0.006). Key differences were confirmed by qRT-PCR (splenocytes) or proteomics (THP-1). These studies demonstrate the complexity of GA's mechanisms of action, and may help inform therapeutic equivalence assessment.
24
Type II monocytes modulate T cell–mediated central nervous system autoimmune disease
Martin S. Weber, Thomas Prod’homme, Sawsan Youssef et al. · Nature Medicine · 2007 · 448 citations